Compare Stocks → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CRBUNASDAQ:HUMANASDAQ:ICVXNASDAQ:PCVXNASDAQ:RUBY Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRBUCaribou Biosciences$3.85-1.5%$5.88$3.44▼$8.59$347.73M2.471.65 million shs1.71 million shsHUMAHumacyte$3.70+3.1%$3.53$1.96▼$5.60$440.60M1.461.09 million shs4.90 million shsICVXIcosavax$15.31$15.32$4.75▼$16.10$766.88M1.281.22 million shsN/APCVXVaxcyte$60.83+0.3%$69.67$41.57▼$82.04$6.62B0.89839,504 shs1.32 million shsRUBYRubius Therapeutics$0.06+2.7%$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,800 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRBUCaribou Biosciences0.00%-9.70%-27.46%-23.63%-12.13%HUMAHumacyte+15.06%+18.87%+2.87%+34.46%+7.16%ICVXIcosavax0.00%0.00%0.00%-0.78%+188.32%PCVXVaxcyte-2.90%-6.49%-10.33%+0.08%+32.39%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%+171.43%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRBUCaribou Biosciences1.4693 of 5 stars3.41.00.00.02.51.70.6HUMAHumacyte2.0148 of 5 stars3.42.00.00.02.22.50.6ICVXIcosavax1.0542 of 5 stars3.20.00.00.00.04.20.0PCVXVaxcyte1.1552 of 5 stars3.52.00.00.00.62.50.0RUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRBUCaribou Biosciences2.75Moderate Buy$22.50484.42% UpsideHUMAHumacyte2.75Moderate Buy$8.00116.22% UpsideICVXIcosavax2.33Hold$26.5073.09% UpsidePCVXVaxcyte3.00Buy$78.5029.05% UpsideRUBYRubius TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest RUBY, ICVX, CRBU, PCVX, and HUMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2024PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$95.004/1/2024HUMAHumacyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.003/26/2024HUMAHumacytePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.003/25/2024HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/19/2024CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $24.002/28/2024PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$73.00 ➝ $95.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRBUCaribou Biosciences$34.48M10.09N/AN/A$4.17 per share0.92HUMAHumacyte$1.57M280.63N/AN/A$0.13 per share28.46ICVXIcosavax$580K1,322.20N/AN/A$5.47 per share2.80PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ARUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRBUCaribou Biosciences-$102.07M-$1.45N/AN/AN/A-296.05%-31.06%-25.73%5/14/2024 (Estimated)HUMAHumacyte-$110.78M-$1.07N/AN/AN/AN/A-199.62%-61.45%5/10/2024 (Estimated)ICVXIcosavax-$91.76M-$2.22N/AN/AN/AN/A-43.06%-39.53%N/APCVXVaxcyte-$402.27M-$4.13N/AN/AN/AN/A-32.04%-29.72%5/13/2024 (Estimated)RUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ALatest RUBY, ICVX, CRBU, PCVX, and HUMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023HUMAHumacyte-$0.25-$0.24+$0.01-$0.24$0.10 millionN/A 3/11/2024Q4 2023CRBUCaribou Biosciences-$0.22-$0.39-$0.17-$0.39$5.17 million$3.56 million2/27/2024Q4 2023PCVXVaxcyte-$0.89-$1.82-$0.93-$1.82N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRBUCaribou BiosciencesN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/AICVXIcosavaxN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRBUCaribou BiosciencesN/A11.9711.97HUMAHumacyte1.204.524.52ICVXIcosavaxN/A18.0618.06PCVXVaxcyteN/A7.547.54RUBYRubius TherapeuticsN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRBUCaribou Biosciences77.51%HUMAHumacyte44.71%ICVXIcosavax92.59%PCVXVaxcyte96.78%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCRBUCaribou Biosciences9.50%HUMAHumacyte23.10%ICVXIcosavax30.59%PCVXVaxcyte3.60%RUBYRubius Therapeutics5.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRBUCaribou Biosciences15890.32 million81.74 millionOptionableHUMAHumacyte164119.08 million91.58 millionOptionableICVXIcosavax6050.09 million34.77 millionOptionablePCVXVaxcyte254108.76 million104.84 millionOptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableRUBY, ICVX, CRBU, PCVX, and HUMA HeadlinesSourceHeadlineVacant Rubius property generating interest after 1 year on marketpbn.com - April 18 at 1:01 AMSensorium Therapeutics Appoints Sam Rasty as Chief Business Officercitizentribune.com - April 17 at 8:01 PMVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'bizjournals.com - March 11 at 5:07 PMRubius Therapeutics Inc RUBYmorningstar.com - November 5 at 8:39 PM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorbostonglobe.com - October 16 at 7:58 AMRuby Dunne Biography & Moviestribute.ca - September 22 at 6:08 PMParenting Vlogger Ruby Franke Held Without Bail on Child Abuse Chargesoxygen.com - September 14 at 8:44 PMYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowtoday.com - September 8 at 6:33 PMRuby Gonzalesdailynews.com - August 21 at 8:30 AMRUBY - Rubius Therapeutics, Inc.uk.finance.yahoo.com - August 2 at 2:37 AMNorth American Morning Briefing: Alphabet, -2-morningstar.com - July 25 at 7:07 AMRuby Rivera, 23ABCturnto23.com - July 1 at 12:54 AMRuby Speakingcomedy.co.uk - June 23 at 3:11 PMRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternativesfinance.yahoo.com - March 2 at 1:59 AMWhatever happened to Ruby?infoworld.com - February 17 at 4:07 PMThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?marketwatch.com - February 14 at 7:55 PMWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?msn.com - February 14 at 9:54 AMThe Wrap: Ruby's moving to Congress Street, launching new French conceptyahoo.com - January 25 at 4:27 AMRuby Wax sparks concern from fans after posting video from hospital bedmirror.co.uk - January 12 at 12:51 AMRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookdailymail.co.uk - January 12 at 12:51 AMFormer Rubius CEO jumps to another Flagship spinoutfinance.yahoo.com - November 18 at 10:30 AMRubius Therapeutics lays off most of its staff, explores salefinance.yahoo.com - November 4 at 12:16 PMRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternativesfinance.yahoo.com - November 3 at 1:47 PMA high flyer out of Flagship implodes — for the last timeendpts.com - November 2 at 5:41 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCaribou BiosciencesNASDAQ:CRBUCaribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.HumacyteNASDAQ:HUMAHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.IcosavaxNASDAQ:ICVXIcosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington. As of February 19, 2024, Icosavax, Inc. operates as a subsidiary of AstraZeneca PLC.VaxcyteNASDAQ:PCVXVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Rubius TherapeuticsNASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.